Easy estimation of renal growth rate in ADPKD


Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the exponential and unlimited enlargement of the total kidney volume (TKV) associated with a decrease in renal function. In the prospective, placebo-controlled tolvaptan efficacy and safety in the management of ADPKD and its outcomes (TEMPO) 3:4 trial a mixed-model repeated-measures analysis was applied to assess a treatment benefit in reducing the TKV increase rate. The proposed equation for height-adjusted TKV increase via just one measurement would be clinically useful, but further studies are needed to validate it on larger number of patients with varying ethnicities and with long-term follow-up.

Read the full article here: https://www.kireports.org/article/S2468-0249(20)31358-9/fulltext